T2 Biosystems strong buy rating!
Seite 3 von 10 Neuester Beitrag: 24.05.23 22:16 | ||||
Eröffnet am: | 20.07.16 18:38 | von: Balu4u | Anzahl Beiträge: | 228 |
Neuester Beitrag: | 24.05.23 22:16 | von: Stefanoieder | Leser gesamt: | 91.333 |
Forum: | Hot-Stocks | Leser heute: | 12 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | | 4 | 5 | 6 | 7 | 8 | 9 | ... 10 > |
https://www.nasdaq.com/de/symbol/ttoo/real-time
https://www.nasdaq.com/de/symbol/ttoo/real-time
T2 Biosystems meldet Zahlen für Q2/19
- Umsatz 2 Mio. $
- Verlust 16 Mio. $
- Cash 28 Mio. $
- fragwürdige Finanzierung
Financing Agreement Highlights:
- The Company entered into two financing agreements that enables the potential access to up to $60 million of additional capital, potentially strengthening its financial position.
- Entered into an At-the-Market (ATM) equity offering agreement with Canaccord Genuity LLC pursuant to which Canaccord will, at the Company’s option, use reasonable best efforts to sell up to $30 million of our common stock at our direction.
- Entered into common stock purchase and registration rights agreements with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor, under which we will have the right and the sole discretion to sell to LPC up to $30 million worth of shares over a 36-month period at market rates based on closing prices in the past 10 days from when a sales of shares may occur, subject to certain limitations under the agreement as further described below under the section titled "Financing Agreement Details".
http://investors.t2biosystems.com/news-releases/...ancial-results-and
T2 erhält Funding von BARDA
"...announced today that it has been awarded a milestone-based contract of initial value of $6 million with a potential value of up to $69 million, if all contract options are exercised, from the Biomedical Advanced Research and Development Authority (BARDA) ..."
http://investors.t2biosystems.com/news-releases/...advance-technology
Zeitpunkt: 17.09.19 17:58
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - Vulgärsprache
Zeitpunkt: 19.09.19 16:24
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - Bleiben Sie bitte sachlich.
Zahlen für Q3/19
- Umsatz 1,6 Mio. $
"The Company believes that an additional $40 million of capital is required to achieve neutral cash flow."
http://investors.t2biosystems.com/news-releases/...ancial-highlights#
vorläufige Zahlen
- Q4/19 Umsatz ~3 Mio. $
- Ende Q4/19 Cash ~ 11 Mio. $
- MK 54 Mio. $
http://investors.t2biosystems.com/news-releases/...ourth-quarter-2019
Zahlen für 2019
- Umsatz 8,3 Mio. $ (davon 3,1 Mio. $ in Q4)
- Verlust 59 Mio. $ (davon 14 Mio. $ in Q4)
- Cash 11 Mio. $
- negatives Eigenkapital
- MK 34 Mio. $
"Management projects revenue for the full year 2020 to range from $14.0 million to $17.0 million,including product revenue between $8.0 million and $10.0 million and research and grant contribution revenue of $6.0 million to $7.0 million "
Angesichts des hohen Verlustes und des niedrigen Cashbestands bin ich eher skeptisch was die kurzfristigen Zukunftsaussichten anbetrifft. Siehe auch Posting #70
http://investors.t2biosystems.com/news-releases/...and-full-year-2019